Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: Experience with single-agent and combination therapy

Keyphrases

• Combination Therapy 100%
• Single-agent Therapy 100%
• B-CLL 100%
• Purine Analogues 100%
• Chronic Lymphocytic Leukemia 66%
• Combination Chemotherapy 66%
• Molecular Targets 33%
• Monoclonal Antibody 33%
• Comorbidity 33%
• Treatment Regimen 33%
• Clinical Experience 33%
• Mechanism of Action 33%
• Progression-free Survival 33%
• Recent Advances 33%
• Clinical Scenarios 33%
• Vaccine Immunotherapy 33%
• Scientific Rationale 33%
• Response Rate 33%
• Chemoimmunotherapy 33%
• Immunomodulatory Drugs (IMiDs) 33%
• Cellular Immunotherapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Lymphatic Leukemia 100%
• Combination Therapy 100%
• Purine Derivative 75%
• Purine 75%
• Chemotherapy 50%
• Molecular Target 25%
• Progression Free Survival 25%
• Glucocorticoid 25%
• Immunotherapy 25%
• Monoclonal Antibody 25%
• Comorbidity 25%

Immunology and Microbiology

• B Cell 100%
• Monoclonal Antibody 50%
• Progression Free Survival 50%
• Immunomodulatory Drug 50%
• Immunotherapy 50%
• Comorbidity 50%
• Glucocorticoid 50%